Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials

Molecular Psychiatry
R-R WuJ-P Zhao

Abstract

Dyslipidemia is one of the most common adverse effects in schizophrenia patients treated with antipsychotics. However, there are no established effective treatments. In this study, data were pooled from two randomized, placebo-controlled trials, which were originally designed to examine the efficacy of metformin in treating antipsychotic-induced weight gain and other metabolic abnormalities. In total, 201 schizophrenia patients with dyslipidemia after being treated with an antipsychotic were assigned to take 1000 mg day-1 metformin (n=103) or placebo (n=98) for 24 weeks, with evaluation at baseline, week 12 and week 24. The primary outcome was the low-density lipoprotein cholesterol (LDL-C) levels. After metformin treatment, the mean difference in the LDL-C value between metformin treatment and placebo was from 0.16 mmol l-1 at baseline to -0.86 mmol l-1 at the end of week 24, decreased by 1.02 mmol l-1 (P<0.0001); and 25.3% of patients in the metformin group had LDL-C ≥3.37 mmol l-1, which is significantly <64.8% in the placebo group (P<0.001) at week 24. Compared with the placebo, metformin treatment also have a significant effect on reducing weight, body mass index, insulin, insulin resistance index, total cholesterol and tr...Continue Reading

References

Jul 1, 1997·Diabetes Care·S M HaffnerM P Stern
Aug 23, 2000·The Journal of Clinical Investigation·H N Ginsberg
Jun 22, 2005·Treatments in Endocrinology·Elena IzkhakovArdon Rubinstein
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Feb 17, 2006·Clinica Chimica Acta; International Journal of Clinical Chemistry·Rita Kohen AvramogluKhosrow Adeli
May 4, 2007·The Journal of Clinical Investigation·Yan ShuKathleen M Giacomini
Jan 10, 2008·JAMA : the Journal of the American Medical Association·Ren-Rong WuLe-Hua Li
Mar 28, 2008·The Journal of Clinical Psychiatry·David C Henderson
Oct 20, 2011·Nature Reviews. Endocrinology·Marc De HertChristoph U Correll
Nov 8, 2011·Cell Metabolism·Karin E Bornfeldt, Ira Tabas
Mar 24, 2012·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Howard M LandoAnuradha P Dua
Apr 18, 2012·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S JellingerUNKNOWN AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis
Apr 24, 2012·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S JellingerUNKNOWN AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis
Sep 12, 2012·Current Cardiology Reports·Ian GrahamZeljko Reiner
May 1, 2013·Current Vascular Pharmacology·Peter P Toth
Jul 10, 2013·Diabetologia·Graham RenaKei Sakamoto
Oct 2, 2013·Indian Journal of Clinical Biochemistry : IJCB·Yonas MullugetaYesehak Worku
Feb 4, 2014·Schizophrenia Research and Treatment·S I BargiotaN V Angelopoulos
Nov 18, 2014·Expert Opinion on Drug Safety·Richard MusilMichael Hamerle
Feb 28, 2015·Kidney International·Manoocher Soleimani
Jun 4, 2015·The New England Journal of Medicine·John A Jarcho, John F Keaney
Oct 21, 2015·The American Journal of Psychiatry·Juliane HeideJamie I Vandenberg

❮ Previous
Next ❯

Citations

May 12, 2018·Molecular Nutrition & Food Research·Jing-Jing Zhu, Jian-Guo Jiang
Sep 18, 2020·Expert Review of Clinical Pharmacology·Xiao ChenZhi-Ping Li
May 13, 2017·International Journal of Psychiatry in Clinical Practice·Alkomiet HasanUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Apr 28, 2017·Journal of Autism and Developmental Disorders·Logan K WinkCraig A Erickson
Mar 1, 2017·Frontiers in Psychiatry·Adonis SferaMichael Cummings
Jun 13, 2018·Chinese Medical Journal·Ahmed Naguy, Dalal El-Sori
Jun 20, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Rong LiXiansheng Huang
Jul 30, 2021·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Rui YangBi-Lian Liu

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01778244
NCT01206153

Software Mentioned

SAS

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.